Follow the 한올바이오파마 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 한올바이오파마 has recorded 37 reports. The latest transaction was disclosed on 1 July 2026 (Purchase). Among the most active insiders: 국민연금공단. Every trade is accessible without an account.
37
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
n/a
13 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Hanall Biopharma es una empresa especializada en el sector de la salud y farmacéutico, que cotiza en el mercado XKRX. Se enfoca en el desarrollo de tratamientos innovadores para diversas enfermedades.